Histologically proven diagnosis of prostate cancer
Evidence of PSA progression despite castrate levels of testosterone (\<50 ng/dL) following orchiectomy or during therapy with luteinizing hormone releasing hormone agonists (LHRH-a)
Patients with non-metastatic or stable metastatic disease
Chromogranin A elevation above normal range (confirmed by a second evaluation at least 1 week later) \[cut off levels will be \> 20 U/L for enzyme linked immunosorbent (ELISA) assay and \> 100 ng/ml for immunoradiometric (IRMA) assay\]
You may not be if
Patients who according to the investigator opinion are candidates to be treated immediately with chemotherapy (e.g. docetaxel)
First line treatment with antiandrogen in monotherapy
Visceral metastasis
Previous or concomitant treatment with a somatostatin analogue
Clareo Health | Study of Lanreotide in Non Metastatic Castration-resistant Prostate Cancer Patients
